News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Luis Raez Shared ASCO and NCODA 2025 Guidelines For Oral Oncolytics And Specialty Pharmacies Podcast
Luis E. Raez/X
Jun 18, 2025, 23:41

Luis Raez Shared ASCO and NCODA 2025 Guidelines For Oral Oncolytics And Specialty Pharmacies Podcast

Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute, shared a post on LinkedIn:

“Our American Society of Clinical Oncology (ASCO) and NCODA 2025 guidelines for oral oncolytics and specialty pharmacies podcast pls review.”

Luis Raez Shared ASCO and NCODA 2025 Guidelines For Oral Oncolytics And Specialty Pharmacies Podcast

More posts featuring Luis E Raez

American Society of Clinical Oncology cancer Luis E. Raez NCODA OncoDaily Oncology
Special Coverage
Drugs
Jun 20, 2025, 02:19
Is Tamoxifen Chemotherapy? Understanding Its Role in Breast Cancer Treatment
Blog
Jun 19, 2025, 17:36
ESTRO Introduces KAYAC+ to Advance Radiation Therapy For Adolescents And Young Adults With Cancer
Blog
Jun 19, 2025, 17:26
XVII CCI LATAM Conference Was a Celebration Of a Growing Community, Unity, and Hope - Childhood Cancer International
Blog
Jun 19, 2025, 17:07
Join The AI For Everyone, Everywhere, Let’s talk about Large Language Models Meeting - SIOP
Blog
Jun 19, 2025, 16:57
David Planchard: We Need to Work Together to Develop The Wave of New Treatments That Is Coming For Our Patients
Blog
Jun 19, 2025, 16:21
Neeraj Agarwal: Poor Outcomes with SOC in mHSPC Prostate Cancer Patients With HRR Mutation
Blog
Jun 19, 2025, 16:12
World Kidney Cancer Day 2025: Uniting for Progress in the Fight Against Renal Cell Carcinoma
Blog
Jun 19, 2025, 16:01
IARC Marks World Kidney Cancer Day with New Video and Project Highlights
Science
Jun 19, 2025, 15:50
Alexey Kulikov Shared An Article on Cancer Vaccines and The Future of Immunotherapy
Opinion
Jun 19, 2025, 15:47
Mostafa Faisal: Primary Refractory AML and Allo-HCT - A 10-Year Retrospective Study from Japan
Blog
Jun 19, 2025, 15:36
Amol Akhade: KEYNOTE-689 - A Turning Point in Resectable HNSCC - Or a Cautious Step Forward?
Drugs
Jun 19, 2025, 15:30
Graham Collins: Nivo-AVD vs BV-AVD in Older Patients (60+) with Hodgkin Lymphoma